Cover Image

Maintenance Therapy in the Era of Quadruplets for Multiple Myeloma: When, What, and for How Long?

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Authors:	Hira Mian, Luciano J. Costa
Format:	Artículo Open Access
Published:	Wiley 2025
Subjects:	American Journal of Hematology
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Quadruplets in newly diagnosed transplant‐ineligible multiple myeloma
by: Rajshekhar Chakraborty, et al.
Published: (2024)

Lymphocyte Kinetics and Outcomes of Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma With Out of Specification Products
by: Sarah Dingli, et al.
Published: (2025)

Clinical Benefit of Early Daratumumab Use in Multiple Myeloma is Undefined
by: Ruben Van Dijck, et al.
Published: (2025)

Genomic Proximity Mapping for Identification of Chromosomal Aberrations in Multiple Myeloma
by: Richard K. Kandasamy, et al.
Published: (2026)

Identification of a CAR‐Derived Clone by NGS‐Based MRD After Fully Human BCMA CAR T‐Cell Therapy in Multiple Myeloma
by: Wenqiang Yan, et al.
Published: (2025)

Predictors of Delayed Responses to Teclistamab in Multiple Myeloma After Initial Non‐Response
by: Rahul Banerjee, et al.
Published: (2025)

Timing and Pattern of Extraosseous Dissemination Are Key Determinants of Survival in Multiple Myeloma
by: Mickael Tordjman, et al.
Published: (2026)

Circulating Tumor Cells in Multiple Myeloma: From Peripheral Clues to Central Insights
by: Benjamin Podvin, et al.
Published: (2026)

Response to “Determinants of Ultra‐Long‐Term Survival in Multiple Myeloma: A Critical Appraisal of Foundational Assumptions and a Call for Biologically Driven Inquiry”
by: Meletios A. Dimopoulos, et al.
Published: (2026)

The Safety and Efficacy of Commercial BCMA‐Directed CAR T‐Cell Therapy in Systemic AL Amyloidosis With Concurrent Myeloma
by: Matthew J. Rees, et al.
Published: (2026)

Optical Genome Mapping ( OGM ): Validation and Clinical Utility in the Cytogenetic Diagnosis of Multiple Myeloma
by: Adela Cisneros, et al.
Published: (2025)

Optimizing Outcomes in Relapsed and Refractory Multiple Myeloma: Personalized Approaches and Adverse Event Management
by: Eirini Katodritou, et al.
Published: (2025)

The Role of Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma With Renal Impairment: A Systematic Review
by: Ioannis Ntanasis‐Stathopoulos, et al.
Published: (2026)

Real‐World Outcomes of Newly Diagnosed Multiple Myeloma Patients Treated With Front‐Line Daratumumab Lenalidomide and Dexamethasone
by: Ricardo D. Parrondo, et al.
Published: (2026)

Extramedullary Disease—Achilles Heel in Myeloma?
by: Shaji Kumar, et al.
Published: (2025)

Determinants of 15‐Year Progression‐Free Survival in Multiple Myeloma; Real‐World Data From a Single Institution
by: Meletios A. Dimopoulos, et al.
Published: (2025)

Outcomes of Post‐Transplant Rh‐ GCSF and Decitabine Maintenance Therapy in Patients With High‐Risk Myeloid Neoplasm
by: Mathias Palmer, et al.
Published: (2025)

Evaluating Minimal Residual Disease Negativity as a Surrogate Endpoint for Treatment Efficacy in Multiple Myeloma: A Meta‐Analysis of Randomized Controlled Trials
by: Ioannis Ntanasis‐Stathopoulos, et al.
Published: (2025)

Level of Clonal Plasma Cells in Hematopoietic Cell Autografts Reflects the Pre‐Transplant Bone Marrow Minimal Residual Disease in Multiple Myeloma Patients
by: Ondrej Venglar, et al.
Published: (2025)

Trends in Smoldering Myeloma Incidence in the United States From Cancer Registries, 2012–2022
by: Rong Wang, et al.
Published: (2026)

A First‐In‐Human Phase 1 Study of a Novel BCMA × CD3 Bispecific T Cell Engager EMB ‐06 in Relapsed or Refractory Multiple Myeloma
by: Peter T. Tan, et al.
Published: (2025)

CM313 Monotherapy in Patients With Relapsed/Refractory Multiple Myeloma or Marginal Zone Lymphoma: A Multicenter, Phase 1 Dose‐Escalation and Dose‐Expansion Trial
by: Huixing Zhou, et al.
Published: (2025)

Reassessing the Duration of Induction Therapy for Newly Diagnosed, Transplant‐Eligible Myeloma Patients in the Context of Quadruple CD38 Monoclonal Antibody‐Based Regimens: Is 24 Weeks Optimal?
by: Meera Mohan, et al.
Published: (2026)

Why We Do Not Recommend That People With High‐Risk Smoldering Myeloma Receive Treatment
by: Ghulam Rehman Mohyuddin, et al.
Published: (2025)

Parameters Associated With Renal Recovery and Survival in Myeloma Patients With Acute Renal Failure to Cast Nephropathy
by: Heinz Ludwig, et al.
Published: (2025)

Impact of Cytogenetic Response to Therapy on Long‐Term Survival in Acute Myeloid Leukemia
by: John Hanna, et al.
Published: (2025)

Characteristics and Survival Outcomes of Solitary Plasmacytomas: A 30‐Year Experience of the Greek Myeloma Study Group on 175 Patients
by: Eirini Katodritou, et al.
Published: (2025)

Long‐Term Outcomes of Stem Cell Transplant in Older Patients With Acute Myeloid Leukemia Treated With Venetoclax‐Based Therapies
by: Keith W. Pratz, et al.
Published: (2026)

Prognostic Implication of Karyotypic Evaluation in Patients With Richter Transformation in the Modern Era
by: Cecelia R. Miller, et al.
Published: (2025)

Normalization of Cerebral Hemodynamics After Gene Therapy in Adults With Sickle Cell Disease
by: Akshay Sharma, et al.
Published: (2025)

Iron restriction in sickle cell disease: When less is more
by: Oswaldo L. Castro, et al.
Published: (2024)

The Association of Age and Frailty With Adverse Events for Bortezomib and Carfilzomib: A Population‐Based Analysis
by: Mackenzie Lemieux, et al.
Published: (2026)

Therapeutic Advances and Future of Therapy in Acute Myeloid Leukemia
by: Farhad Ravandi
Published: (2025)

Peri‐Transplant Management of JAK Inhibitor Therapy in Myelofibrosis
by: Ayalew Tefferi, et al.
Published: (2024)

The Role of Allogeneic Hematopoietic Cell Transplantation in the Management of Philadelphia Chromosome‐Positive Acute Lymphoblastic Leukemia in the Era of Tyrosine Kinase Inhibitors
by: Ivan Pasic, et al.
Published: (2026)

CD30 as a Target Molecule in the Diagnosis and Therapy of Lymphomas
by: Harald Stein, et al.
Published: (2025)

Crizanlizumab and sickle cell disease: When should medications have their approval status revoked?
by: Jeremy W. Jacobs, et al.
Published: (2024)

Adult Acute Lymphoblastic Leukemia: 2025 Update on Diagnosis, Therapy, and Monitoring
by: Hagop Kantarjian, et al.
Published: (2025)

Chronic Lymphocytic Leukemia: 2025 Update on the Epidemiology, Pathogenesis, Diagnosis, and Therapy
by: Michael Hallek
Published: (2025)

Toward Improving Initial Therapy of Acute Graft Versus Host Disease
by: Ansh Krishnachandra Mehta, et al.
Published: (2025)